EUVIMEDEUVIMED entdecken
Open Access

Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy

Christian Corsini, Hans Garmo, Andri Wilberg Orrason, Rolf Gedeborg, Pär Stattin, Marcus Westerberg

JAMA Network Open · 2023

DOI: 10.1001/jamanetworkopen.2023.36604 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2023. Verfasst von Christian Corsini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Recently, life-prolonging treatments for patients with advanced prostate cancer have been introduced in clinical practice.

Objective

To investigate if the introduction of doublet therapy is associated with changes in survival on a population-basis. Design, Setting, and Participants This nationwide population-based cohort study used data from the Prostate Cancer data Base Sweden from 2008 to 2020. Men registered with de novo metastatic castration-sensitive prostate cancer (mCSPC) were included. Exposure The proportion of men with mCSPC who received doublet therapy, ie, androgen deprivation therapy plus androgen receptor pathway inhibitor drugs or chemotherapy was assessed. Main Outcomes and Measures Standardized overall survival, taking age, comorbidity, and cancer characteristics into consideration, was estimated by use of a parametric survival model.

Results

A total of 11 382 men were included in this study (median [IQR] age, 74.0 [68-81] years). There was a shift toward less advanced prostate cancer during the study period with a decrease in median (IQR) prostate-specific antigen at diagnosis in men with mCSPC from 145 (39-571) ng/mL to 107 (27-426) ng/mL. Upfront treatment with doublet therapy in these men simultaneously increased from 1% (7 of 991) in 2016 to 44% (402 of 922) in 2020. The adjusted 5-year overall survival increased from 26% (95% CI, 25%-28%) from 2008 to 2012 to 35% (95% CI, 31%-40%) from 2017 to 2020. During the first 5 years after diagnosis, there was an increase in mean survival of 6 months, from 2.7 (95% CI, 2.6-2.8) years from 2008 to 2012 to 3.2 (95% CI, 3.1-3.1) years from 2017 to 2020. Conclusions and Relevance In parallel with improvements in treatment of advanced prostate cancer, a clinically meaningful increase in mean survival was observed in men with de novo mCSPC in Sweden between 2008 and 2020 in this study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMaleHumansAgedAndrogen AntagonistsCohort StudiesProstate-Specific AntigenAndrogen Receptor Antagonists

Substanzen

Androgen AntagonistsProstate-Specific AntigenAndrogen Receptor Antagonists

Autor:innen und Institutionen

  • Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
  • Division of Experimental Oncology/Unit of Urology, URI Institution, IRCCS San Raffaele Hospital, Milan, Italy.
  • Medical Products Agency, Stockholm, Sweden.

Zitieren

APA

Corsini, C., Garmo, H., Orrason, A. W., Gedeborg, R., Stattin, P., & Westerberg, M. (2023). Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.36604

Vancouver

Corsini C, Garmo H, Orrason AW, Gedeborg R, Stattin P, Westerberg M. Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2023.36604

BibTeX
@article{Corsini2023,
  author = {Corsini, Christian and Garmo, Hans and Orrason, Andri Wilberg and Gedeborg, Rolf and Stattin, Pär and Westerberg, Marcus},
  title = {Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy},
  journal = {JAMA Network Open},
  year = {2023},
  doi = {10.1001/jamanetworkopen.2023.36604}
}
Kostenlos starten →